Speculation that Moderna, Inc.’s Spikevax windfall could lead to an interest in mergers and acquisitions has gained added substance as the company indicated during its first quarter sales and earnings call that it is looking at potential deals around the world. At the same time, while Q1 revenues beat consensus expectations, analysts are bracing for the possibility of lower revenue as the COVID-19 pandemic becomes endemic.
The company unveiled its first quarter earnings on 4 May, including revenues that beat analyst estimates and projections that it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?